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 Introduction 
 Neurodegenerative tauopathies include frontotempo-
ral lobar degeneration (FTLD) and tauopathies with 
prominent extrapyramidal features like progressive su-
pranuclear palsy (PSP), corticobasal degeneration (CBD), 
and hereditary frontotemporal dementia with Parkinson-
ism linked to chromosome 17 associated with  tau gene 
mutations (FTDP-17 T )  [1–3] . Although distinct clinical 
and neuropathological criteria have been elaborated 
which allow differentiation between these disorders, clin-
ical and pathological overlap is frequently seen  [4–6] . In 
addition to FTLD with tau-positive inclusions (FTLD-
tau), FTLD may be associated with TDP-43 (TAR DNA-
binding protein 43)-positive inclusions (FTLD-TDP), FUS 
(fused in sarcoma)-positive inclusions (FTLD-FUS), or 
may be linked to chromosome 3 (FTD-3; FTLD-UPS)  [7] . 
 Alternative mRNA splicing of  MAPT leads to six tau 
isoforms in the adult human brain, consisting of three tau 
isoforms with four tandem repeats (4R), and three iso-
forms with three repeats (3R). In normal adult human 
brains, similar levels of 3R and 4R tau isoforms are pres-
ent  [8] . The molecular hallmark of neurodegenerative 
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 Abstract 
 Neurodegenerative tauopathies may be inherited as autoso-
mal-dominant disorders with variable clinicopathological 
phenotypes, and causative mutations in the microtubule-
associated protein tau ( MAPT  ) gene are not regularly seen. 
Herein, we describe a patient with clinically typical and au-
topsy-proven corticobasal degeneration (CBD). Her mother 
was diagnosed to have Parkinson’s disease, but autopsy 
showed CBD pathology as in the index patient. The sister of 
the index patient had the clinical symptoms of primary pro-
gressive aphasia (PPA), but no pathology was available to 
date. Molecular analysis did not reveal any mutation in the 
 MAPT or progranulin ( GRN ) genes. Our findings illustrate that 
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tauopathies is the aggregation of particular tau isoforms. 
In extrapyramidal tauopathies, like PSP, CBD, and a sub-
set of FTDP-17 T families, aggregation of predominantly 
4R tau isoforms was demonstrated, while in others tauop-
athies filamentous tau aggregates may consist predomi-
nantly of 3R (Pick’s disease), 4R (argyrophilic grain dis-
ease) or a mixture of both, 3R and 4R tau isoforms (subset 
of FTDP-17 T cases)  [1, 9] . 
 A hereditary 4R extrapyramidal tauopathy caused by 
 MAPT mutations was initially described in families with 
the FTDP-17 phenotype  [10] . Later it was recognized that 
different members of the same kindred with hereditary 
4R extrapyramidal tauopathy may exhibit diverse symp-
toms encompassing the features of FTDP-17, PSP or CBD 
 [6, 11] . In addition, sporadic PSP and CBD share a com-
mon MAPT haplotype that increases risk for disease  [12, 
13] . Therefore, the clinical and pathological phenotypes 
of hereditary 4R tauopathies may represent different 
points within one disease spectrum. Since  MAPT muta-
tions were not regularly found in patients with heredi-
tary tauopathies, additional genetic or epigenetic factors 
might contribute to the phenotypic diversity.
 Here, we describe a family with an autosomal-domi-
nant 4R tauopathy without pathogenic  MAPT or  GRN 
 mutation with phenotypic variation, manifesting as CBD, 
parkinsonism or, presumably, primary progressive apha-
sia (PPA).
 Patients and Methods 
 The family originates from the German-speaking part of Swit-
zerland ( fig. 1 ). All consenting family members underwent neu-
rological examination, neuropsychological testing and molecular 
genetic analysis. Extended laboratory analysis, magnetic reso-
nance imaging (MRI), and [ 18 F]-FDG (2-fluoro-2-deoxy-glucose) 
positron emission tomography (PET) were performed in the in-
dex patient and her sister. In addition, available medical records 
of the deceased family members were studied. Brain autopsy was 
performed in the index patient (II-2) and paraffin-embedded tis-
sue was available from a former autopsy of her mother (I-2).
 Molecular Genetic Analysis 
 DNA was extracted using standard protocols (QIAamp, 
QIAGEN, Hilden, Germany). Primer sequences were designed ac-
cording to GenBank entries and are available on request. PCR 
amplification was done by a universal ‘touch down’ protocol, and 
amplicons were sequenced by fluorescent dye dideoxy termina-
tors on an ABI PRISM  (Applied Biosystems, Forster City, Calif., 
USA). Exons 1, 7, 9–13 and 16 of the  MAPT gene, including the 
flanking intronic regions, were analyzed, thus covering all ge-
nomic regions with known mutations.  GRN sequence analysis 
was performed as previously described  [14] .
 Neuropathology 
 Brain autopsy was performed in the index patient. From her 
mother, paraffin-embedded brain tissue was available for re-eval-
uation. No brain tissue was available from the index patient’s sis-
ter. 
 From the index patient, sections (3   m) were subjected to con-
ventional stains, including the Gallyas silver technique. Immuno-
histochemistry was performed with anti-tau antibodies AT8 
(phospho-epitopes Ser202 and Thr205; Innogenetics, Ghent, Bel-
gium), RD3 (3R tau isoform; Upstate, Lake Placid, N.Y., USA), 
RD4 (4R tau isoform; Upstate), alpha-synuclein (human alpha-
synuclein; Zymed, San Francisco, Calif., USA),   A4 (human beta-
amyloid; DAKO, Glostrup, Denmark), 3F4 (PrP; Signet, Denham, 
Mass., USA), neurofilament (SMI31; phosphorylated epitopes on 
the largest neurofilament subunit; Sternberger Monoclonals, Lu-
therville, Mass., USA),   B-crystallin (Novocastra, Newcastle-up-
on-Tyne, UK) and glial fibrillary acidic protein (GFAP; Lab Vi-
sion Corporation, Newmarket, Suffolk, UK). Sarkosyl-insoluble 
tau proteins were extracted from the index patient’s frontal and 
temporal cortices, hippocampus, striatum and spinal cord. West-
ern blot analysis, electron microscopy and immuno-electron mi-
croscopy were performed as previously described  [15] . Micro-
graphs were recorded at a magnification of  ! 40,000 (Philips 
EM208S microscope). Dephosphorylation assays were performed 
as previously described  [15] . 
 Results 
 Case Report of the Index Patient  
 At 54 years, the right-handed patient (II-2) had diffi-
culties to recognize traffic signs or to relocate her car on 
a parking lot. During the following months, clumsiness 
of her left hand developed, and she became unable to 
work as a beautician. One year later, the first neurological 
examination at our department revealed psychomotor 
slowing, left homonymous hemianopsia, marked dysto-
3
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 Fig. 1. Pedigree. The arrow indicates the index patient. Circles 
represent females, and squares represent males. Filled symbols 
represent affected family members. Open symbols represent clin-
ically unaffected individuals. 
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nia of the left arm without spasticity and slight distal 
weakness (MRC grade M4–5). Muscle tone, strength, and 
coordination of the right arm and both legs were normal. 
No involuntary movements were observed. Tendon re-
flexes were brisk on the left and normal on the right side, 
plantar responses were flexor. Sensory examination re-
vealed impaired joint position sense on the left side. Cog-
nitive testing demonstrated a right parietal lobe syn-
drome with neglect, agnosia for affective facial expres-
sions, visuoconstructive deficits, ideomotor apraxia and 
figural, but not verbal, memory deficits. Language func-
tions were preserved. CSF examination as well as extend-
ed laboratory investigations were normal. 
 Based on the clinical findings, CBD was assumed. Two 
years after onset, neurological examination revealed 
marked dystonia of the left arm with almost complete loss 
of functionality due to dystonia, apraxia, and neglect. 
The other neurological findings were unchanged and no 
alien limb phenomenon had developed. Repeated CSF 
analysis showed strong positivity for protein 14-3-3. Over 
the following three years, she progressively deteriorated. 
Dystonia generalized, albeit predominance of the left 
arm remained, she became wheelchair-dependent and fi-
nally bedridden. Five and a half years after onset she sud-
denly reported severe abdominal pain. Colon perforation 
was diagnosed and she died 36 h later due to septic peri-
tonitis. 
 Family Evaluation  
 The father of the index patient died at the age of 90 
years without history of psychiatric or neurological prob-
lems. After 61 years, the mother of the index patient de-
veloped progressive gait problems, frequent falls, brady-
kinesia, cognitive deterioration, and swallowing difficul-
ties, and parkinsonism was diagnosed. At the age of 73 
years she died due to cardio-respiratory failure. Retro-
spectively, the predominant gait problems are suggestive 
of a PSP-like phenotype.
 The sister (II-3) of the index patient had progressive 
word-finding difficulties after 60 years. At 62 years, she 
demonstrated isolated deficits in language functions, 
including stagnant spontaneous speech, word-finding 
difficulties, semantic and phonematic paraphasias, and 
mild paragrammatism. Reading was slow and stagnant, 
and there were paralexias of long words. Repetition and 
writing of dictated long and complex sentences were er-
roneous. Language comprehension was intact. No defi-
cits in other cognitive functions were identified, and she 
was diagnosed with PPA. 
 The other relatives of the index patient did not report 
psychiatric or neurological symptoms, and neurological 
examination was normal. One sibling (II-4) had normal 
cognitive function. One sibling (II-1) had minimal im-
pairment of verbal retrieval and verbal error checking. 
Another sibling (II-5) had slight impairment of figural 
short-term memory ( table 1 ).
 Neuroradiology 
 MRI of the index patient showed bilateral, right-dom-
inant parietal lobe atrophy and symmetrical, periventric-
ular confluating T 2 -hyperintense white matter lesions 
predominantly located in the parieto-occipital regions 
( fig. 2 a, b). FDG-PET demonstrated decreased FDG up-
take of the right hemisphere associated with cerebellar 
diaschisis ( fig. 2 e, f). Follow-up cerebral MRI document-
ed slight progression of right hemispheric cortical atro-
phy whereas the leukoencephalopathy remained un-
changed ( fig. 2 c, d). Repeated cerebral FDG-PET suggest-
ed a progressive impairment of the right hemispheric 
glucose metabolism, and increasing cerebellar diaschisis 
( fig. 2 g, h). The sister (II-3) with PPA had normal cerebral 
FDG-PET. Brain MRI showed diffuse white matter le-
sions in both hemispheres, predominantly located in 
frontal and periventricular regions (data not shown). 
 Molecular Genetic Analysis 
 None of the examined individuals showed mutations 
in the genomic regions of the  MAPT gene with known 
mutations or in the  GRN gene.  PRNP  sequence analysis 
Table 1. C linical and molecular characteristics
Pro-
band
Age Gen-
der
PRNP 
deletion 
analysis
PRNP 
codon 
129
Neurological 
phenotype
Cognitive 
abnormalities 
I-2 73 f del/wt n.a. Parkinsonian 
syndrome
n.p.
II-1 59 m del/wt M/M normal (+)
II-2 57 f del/del M/M CBD +++
II-3 55 f del/wt M/M PPA +
II-4 53 m del/wt M/V normal none
II-5 51 f del/del M/M normal (+)
III-1 32 f del/wt M/M normal n.p.
d el/wt = Heterozygous 24-bp deletion in the PRNP gene; del/
del = homozygous 24-bp deletion in the PRNP gene; none = no 
cognitive abnormalities; (+) = slight and probably unspecific cog-
nitive abnormalities; +++ = severe cognitive abnormalities; n.p. = 
not performed.
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of the index patient (II-2) revealed a homozygous 24-bp 
deletion in the octapeptide repeat region in the PRNP 
gene starting at codon 66. Due to the high homology in 
this region the precise location of the repeat could not be 
determined. One sibling (II-5) was also homozygous for 
the 24-bp deletion while all other siblings were heterozy-
gous ( table 1 ). The mother of the index patient was het-
erozygous. No heterozygous 24-bp deletion in the  PRNP 
gene was found in 200 healthy individuals. Individual 
II-4 was heterozygous for the Met/Val polymorphism at 
codon 129 whereas the other siblings were homozygous 
for the Met allele ( table 1 ).
 Neuropathology 
 External examination of the index patient’s brain re-
vealed slightly asymmetric cortical atrophy which was 
most pronounced in the right superior frontal and pari-
etal lobes, while the temporal and occipital lobes were 
almost spared. Coronal sections revealed thinning of the 
corpus callosum and enlargement of the lateral and third 
ventricles. Transverse sections of the brainstem showed 
pallor of the substantia nigra pars compacta and to a less-
er degree of the locus coeruleus. 
 Histologically, marked neuronal loss, astrocytic glio-
sis and superficial spongiosis were present in the atrophic 
cortical regions ( fig. 3 a). The adjacent subcortical white 
matter displayed mild to moderate myelin loss and glio-
sis. In affected cortical areas, mainly in the parietal lobe, 
scattered ballooned neurons (BN) were noted, immuno-
histochemically staining for neurofilament,   B-crystal-
lin, and tau antibodies AT8 and RD4 ( fig.  3 b). Gallyas 
silver staining, AT8 and RD4 immunohistochemistry re-
vealed numerous astrocytic plaques ( fig. 3 c). A few astro-
cytic tau inclusions were reminiscent of tufted astrocytes. 
Besides BN, cortical neuronal tau pathology was charac-
terized by perinuclear rim-like inclusions, Pick body-like 
inclusions and some tangle-like inclusions ( fig. 3 d). Neu-
ronal tau pathology was further noted in basal ganglia, 
thalamus, substantia nigra and locus caeruleus ( fig. 3 f). 
Abundant neuropil threads were noted in affected corti-
b c da
fe g h
 Fig. 2. Imaging.  a Flair images show hyperintense symmetrical 
periventricular confluating white matter lesions predominantly 
located in the parieto-occipital regions, and less prominently in 
the frontal white matter and the splenium of the corpus callosum. 
There were no signal abnormalities in basal ganglia and thalamus. 
 b Flair images demonstrate right-dominant bilateral parietal lobe 
atrophy.  c T2, and  d f lair repeated cerebral MRI 2 years later doc-
uments a clear progression of hemispheric cortical atrophy, with 
unchanged posterior leukencephalopathy.  e ,  f FDG-PET demon-
strates markedly decreased FDG uptake of the right hemisphere. 
 g ,  h Repeated cerebral FDG-PET suggest a slightly progressive 
impairment of the right hemispheric glucose metabolism, and in-
creasing cerebellar diaschisis. 
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cal and subcortical gray and white matter areas ( fig. 3 e, 
f). In white matter areas, there were also numerous coiled 
bodies.   -Amyloid plaques, neurofibrillary flame-shaped 
tangles (except few in sector CA2 of the hippocampus), 
argyrophilic grains as well as Lewy bodies and Lewy neu-
rites were absent (data not shown). Western blot analysis 
of brain homogenates revealed no PrP Sc (data not shown).
Based on these findings, the neuropathological analysis 
confirmed the clinical diagnosis of CBD. 
 The diagnosis of CBD was further corroborated by 
Western blot analysis of sarkosyl-insoluble tau extracted 
from various regions of the index patient’s brain. Anti-
bodies AT8 and AT100 strongly labeled two bands at 68 
and 64 kDa ( fig. 4 b). A slight band at 60 kDa was also ob-
served in the hippocampus of the index patient which is 
most likely due to the presence of some neurofibrillary 
tangles found in sector CA2 (see above). By electron mi-
croscopy, filaments in the sarkosyl-insoluble tau extracts 
were labeled with antibody AT8 ( fig. 4 a). Filaments were 
predominantly ‘narrow twisted ribbons’ as reported in 
other hereditary tauopathies  [16] . SDS-PAGE revealed the 
presence of 3R and 4R tau isoforms in similar ratios in-
distinguishable from soluble tau extracted from a control 
brain ( fig. 4 c). The soluble tau fraction yielded no pattern 
shift following treatment with lambda-phosphatase, and 
the bands aligned with all six isoforms of recombinant 
tau ( fig. 4 c). In contrast, lambda-phosphatase treatment 
of sarkosyl-insoluble tau from the temporal cortex of the 
index patient caused a shift in the band pattern visualized 
by BR134 and HT7 staining with bands aligning predom-
inantly with 4R recombinant tau isoforms ( fig. 4 d).
 Records from the index patient’s mother reported 
‘brain atrophy’ without further specifications. Histologi-
cally, mild neuron loss and astrogliosis were found in the 
striatum while the hippocampus and cerebellum were 
normal. In the striatum, Gallyas stain and AT8 immu-
nostaining revealed abundant neuropil thread-like pro-
cesses in the internal capsule, in the pencil fibers, but also 
in gray matter of the striatum ( fig. 5 a, b). In the latter, 
there was neuronal tau-pathology, sometimes shaped as 
globose neurofibrillary tangles ( fig. 5 c). Tufted astrocytes 
were not noted. Tau-pathology was strongly stained with 
anti-tau antibodies AT8 and RD4 ( fig. 5 c), but not with 
antibody RD3 direct against 3R tau isoforms ( fig.  5 d). 
a b c
d e f
 Fig. 3. Brain autopsy findings of the index patient. HE-stained 
sections of the parietal cortex showing marked neuronal loss, as-
trogliosis and spongiosis ( a ) together with some ballooned cells 
( b ). Cortical AT8 stained astrocytic plaques ( c ) and neuronal tau 
pathology ( d ). Gallyas silver stain reveals abundant white matter 
neuropil thread-like structures and coiled bodies ( e ). Gallyas 
stained thread-like structures in pencil fibers of the striatum in 
addition to an astrocytic plaque and neuronal tau pathology ( f ).
 a  ! 100;  b  ! 150;  c–f  ! 200. 
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Abundant tau-pathology was further noted in a small 
strip of the subcortical insular white matter ( fig. 5 e). In 
hippocampal sector CA2, several neurofibrillary tangles 
(NFT) were visualized by Gallyas and AT8 staining 
( fig. 5 f). There were no NFT in other hippocampal sectors 
and adjacent parahippocampal cortex. Selective neurofi-
brillary degeneration of hippocampal sector CA2 has re-
cently been described in 4R tauopathies  [17] .   -Amyloid 
plaques, PrP Sc deposits (3F4 immunohistochemistry) and 
Lewy pathology were absent (data not shown). 
d
a b
c
 Fig. 4. EM and biochemical analysis of tau pathology of the index 
patient.  a Electron micrograph of tau filaments isolated from the 
sarkosyl-insoluble tau fraction shows labelling with antibody 
AT8. Scale bar = 100 nm.  b Immunoblot of sarcosyl-insoluble tau 
stained with antibodies AT8 and AT100 shows two major bands 
at 68 and 64 kDa in the frontal (F) and temporal (T) cortex, hip-
pocampus (Hi), and striatum (S) but not in the spinal cord (Sp) 
which was found to be devoid of tau pathology. The slight tau 
band at 60 kDa in the hippocampus is likely due to the presence 
of some paired helical filaments. Immunoblot of PHF-tau extract-
ed from the brain of an Alzheimer patient (AD) shows three major 
bands at 68, 64 and 60 kDa. c BR134 staining reveals similar ratios 
of 3R and 4R tau isoforms in the heat stable soluble tau fraction of 
the index patients frontal (F.ctx) and temporal (T.ctx) cortex 
when compared to a control (Ctrl) brain. No shift is observed af-
ter lambda-phosphatase (+) treatment and the bands align with 
all isoforms of recombinant tau (RT).  d Sarkosyl-insoluble tau de-
phosphorylated with lambda-phosphatase (+) and immunoblot-
ted with phosphorylation-independent anti-tau antibodies BR134 
and HT7. Two major bands align predominantly with recombi-
nant 4R tau isoforms (4R0N and 4R1N). Immunoblotting with 
phosphorylation-dependent anti-tau antibody AT8 confirms ef-
ficient dephosphorylation of the sample while Ponceau staining 
shows similar protein loading. 
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 Although there were limitations in the pathological 
investigation of the index patient’s mother, histological 
and immunohistochemical features were strongly sug-
gestive for CBD.
 Discussion 
 The index patient fulfilled the proposed clinical criteria 
for CBD including asymmetrical rigidity and dystonia 
nonresponsive to  L -dopa with insidious onset and progres-
sive course, signs of cortical dysfunction including apraxia 
and hemineglect  [3, 18] . The neuroradiological findings 
were in line with this diagnosis, demonstrating progressive 
asymmetrical cortical atrophy with frontoparietal pre-
dominance supported  [19] . In the index patient’s mother, 
diagnosis of Parkinson’s disease was made. History of pro-
gressive gait problems, frequent falls, and bradykinesia 
suggested a PSP-like phenotype. The histopathological 
findings, however, confirmed the diagnosis of CBD, thus 
being compatible with autosomal-dominant inheritance 
 [20] . In both patients, there were no early language deficits 
such as paraphasias or word-finding difficulties. By con-
trast, the sister of the index patient (II-3) suffers from PPA 
without evidence for a movement disorder. 
 The family pedigree suggests autosomal-dominant in-
heritance of a neurodegenerative disease presenting as 
CBD, Parkinsonism (possibly PSP) and PPA. Since no 
pathological examination is available in the index case’s 
sister with PPA, a different pathologic phenotype such as 
tau- or TDP-43-positive frontotemporal dementia (FTD) 
cannot formally be excluded. In the affected family mem-
bers, we were unable to detect a causative mutation in 
 MAPT . Similarly, in other families with hereditary PSP/
CBD, mutational screening of the  MAPT gene revealed 
no evidence for a pathogenic mutation  [11] . Pathogenic 
 MAPT mutations were only found in a subset of families 
with hereditary PSP despite extensive analysis of the 
 MAPT gene  [21–24] . Although we cannot exclude that a 
 MAPT mutation could have been missed by our muta-
tional screening, causative mutations in other genes up- 
or downstream the tau metabolic pathway might be pres-
ent. Although mutations in  GRN are mainly linked to 
FTLD with TDP-43 pathology, they can also be associ-
a b c
d e f
 Fig. 5. Histopathological findings of the index patient’s mother. 
Gallyas stain of the striatum shows abundant thread-like struc-
tures, neuronal tau pathology and coiled bodies in the gray matter 
( a ) as well as in the pencil fibers ( b ). Thread-like structures and a 
globose tangle stained with anti-tau antibody RD4 recognizing 
4R tau isoforms ( c ). Tau pathology is not detected by anti-tau an-
tibody RD3 directed against 3R tau isoforms ( d ). Abundant white 
matter tau-pathology obtained with Gallyas silver stain ( e ). AT8 
stained neurofibrillary tangles in sector CA2 of the hippocampus 
( f ).  a–e  ! 200;  f  ! 100. 
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